In Acute Ischemic Stroke subjects that did not receive alteplase, treatment with nerinetide increased the proportion of patients who had a good functional outcome by 9.5% (a relative improvement of 19% over the placebo group), reduced mortality by about 40%, and reduced the volume of the strokes by about 22%.